Literature DB >> 18618370

Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy.

Merete Alice Lyngstad-Brechan1, Erik Taubøll, Karl Otto Nakken, Leif Gjerstad, Kristin Godang, Rune Jemtland, Jens Bollerslev.   

Abstract

OBJECTIVES: The aims of this study were to assess the occurrence of osteoporosis and fracture rate in Norwegian postmenopausal women with epilepsy using antiepileptic drugs (AEDs), and to investigate how AEDs may affect bone health.
MATERIAL AND METHODS: Twenty-six female patients receiving AED monotherapy and 26 individually matched healthy controls answered questions about their general health, lifestyle and previous fractures. For both groups, bone mineral density (BMD) was measured by DEXA, and serum samples were analysed for biochemical bone turnover markers and haematological parameters.
RESULTS: The patients, particularly those treated with enzyme-inducing AEDs, had significantly lower BMD than the controls. Additionally, 62 % of the women with epilepsy had osteoporotic T-values in one or more regions, compared with 27 % in the control group. There was a non-significant tendency towards an increased fracture rate among the patients. Markers for bone formation (ALP, bALP, osteocalcin) and bone resorption (Crosslaps) were elevated in the patient group compared with the controls.
CONCLUSIONS: Compared with the healthy controls, we found an increased occurrence of osteoporosis, probably due to increased bone turnover, among Norwegian postmenopausal women with epilepsy undergoing AED monotherapy, which may render these women especially vulnerable to fractures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618370     DOI: 10.1080/00365510802233442

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

Review 1.  Medication-induced osteoporosis: screening and treatment strategies.

Authors:  Keshav Panday; Amitha Gona; Mary Beth Humphrey
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-10       Impact factor: 5.346

Review 2.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

3.  General surgery among long-term residents with and without active epilepsy at the Kork Epilepsy Centre - a prospective comparative one-year survey.

Authors:  Bernhard J Steinhoff; Ralph Hartmann; Matthias Luy; Angelika Rombach; Gerhard Ziegler; Jürgen Schulte-Mönting; Frank G Gilliam
Journal:  Eur Neurol       Date:  2010-08-03       Impact factor: 1.710

Review 4.  Osteoporosis Associated with Epilepsy and the Use of Anti-Epileptics-a Review.

Authors:  Sandra J Petty; Helen Wilding; John D Wark
Journal:  Curr Osteoporos Rep       Date:  2016-04       Impact factor: 5.096

Review 5.  A review of the effect of anticonvulsant medications on bone mineral density and fracture risk.

Authors:  Richard H Lee; Kenneth W Lyles; Cathleen Colón-Emeric
Journal:  Am J Geriatr Pharmacother       Date:  2010-02

6.  The association of newer anticonvulsant medications and bone mineral density.

Authors:  Richard Lee; Kenneth Lyles; Richard Sloane; Cathleen Colón-Emeric
Journal:  Endocr Pract       Date:  2012-09-14       Impact factor: 3.443

7.  Effect of topiramate on acid-base balance: extent, mechanism and effects.

Authors:  Nasir Mirza; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

8.  Bone Health in Rats With Temporal Lobe Epilepsy in the Absence of Anti-Epileptic Drugs.

Authors:  Rhys D Brady; Ker Rui Wong; Dale L Robinson; Richelle Mychasiuk; Stuart J McDonald; Ryan A D'Cunha; Glenn R Yamakawa; Mujun Sun; John D Wark; Peter Vee Sin Lee; Terence J O'Brien; Pablo M Casillas-Espinosa; Sandy R Shultz
Journal:  Front Pharmacol       Date:  2019-10-29       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.